In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday issued two final guidances, in which it recommended against making Eisai and Biogen's Leqembi (lecanemab) and Eli ...

A routine medical appointment revealed the first sign of early-onset dementia for Jim Rogers, a 58-year-old British man ...

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

And more pharma news updates from Pharmalittle.

Jim Rogers, 58, was living and working in Australia when he started to develop symptoms of the incurable neurological ...

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

The National Institute for Health and Care Excellence (NICE) has maintained its decision not to recommend two treatments for Alzheimer’s disease on the NHS, after concluding that they still do not ...